Determining the level of fibrosis is key in evaluating patients for HBV treatment candidacy. How, when, and why should we incorporate fibrosis assessments into clinical practice? Here’s my take.
How I incorporate family history into HBV treatment and monitoring decisions in certain clinical gray zones.
This concise MedicalMinute presentation reviews the natural history of HBV infection and interpreting serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
This concise MedicalMinute presentation reviews the AASLD guidelines on monitoring and treatment for patients with HBV infection, including a brief discussion of HCC risk in various patient populations.
This concise MedicalMinute presentation reviews the AASLD recommendations on methods to assess liver fibrosis and inflammation and data and guidance on translating test results into management decisions.
In episode 2 of this ongoing series, listen to a conversation between Robert G. Gish, MD, FAASLD, and patient and advocate, Alan Wang, on approaches to destigmatize HBV infection and remove barriers to care.
Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
Review key data and AASLD guideline recommendations on HCC risk, considerations for treatment, and optimal HCC monitoring.
Review key data and AASLD guideline recommendations on methods to evaluate liver fibrosis and inflammation to guide management decisions for patients with HBV infection.
Assessment of liver disease severity is often overlooked in the management of patients with HBV infection, but it can tip the scales when weighing the decision to treat or monitor.
This concise MedicalMinute presentation reviews the APASL guidelines on treatment indications for patients with HBV infection, including a brief discussion of methods to assess fibrosis.
In episode 1 of this ongoing series, listen to a conversation between Grace LH Wong, MD, and her patient, Ms. Chan, on the shared decision for Ms. Chan to start treatment for hepatitis B infection during her pregnancy.
Review APASL guideline recommendations informing HBV treatment candidacy, including fibrosis assessments and ongoing monitoring.